Key result
L3MBTL4 loss sensitizes PDAC cells to DNA-PK inhibitor NU7441, with methylation affecting ~28% of tumors.
Why the study?
The mechanism and potential therapeutic strategies involving the L3MBTL4 gene in pancreatic ductal adenocarcinoma were not fully understood.
Does L3MBTL4 methylation sensitize pancreatic ductal adenocarcinoma cells to DNA-PK inhibitors?
Population
43 intraductal papillary mucinous neoplasms, 21 mucinous cystic neoplasms, 298 PDAC tissue samples, and xenograft mouse models
Comparison
L3MBTL4 expression or knockdown vs controls and sensitivity to NU7441
Design
Preclinical in vitro and xenograft mouse model study with human tissue analysis
Authors
Loading...
L3MBTL4 methylation in PDAC precursors is hypothesis-generating; leaves open epigenetic targeting pending clinical validation.
Does L3MBTL4 methylation sensitize pancreatic ductal adenocarcinoma cells to DNA-PK inhibitors?
Epigenetic silencing of L3MBTL4 sensitizes pancreatic cancer cells to DNA-PK inhibitors, suggesting a potential targeted therapeutic strategy.
Yao et al. (2026) studied Pancreatic ductal adenocarcinoma (PDAC) (n=362). L3MBTL4 methylation was evaluated on L3MBTL4 methylation rate in PDAC. L3MBTL4 was methylated in 28.2% of pancreatic ductal adenocarcinomas, and its loss sensitized PDAC cells to the DNA-PK inhibitor NU7441.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: